Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Journal of gastrointestinal oncology
View this publicationJournal of gastrointestinal oncology
View this publicationThe Cochrane database of systematic reviews
View this publicationBiology
View this publicationLangenbeck's archives of surgery
View this publicationPathogens (Basel, Switzerland)
View this publicationJournal of biosciences
View this publicationJournal of clinical medicine
View this publicationChirurgie (Heidelberg, Germany)
View this publicationClinical transplantation
View this publicationFrontiers in surgery
View this publication